###  [:house:返回首頁](https://github.com/ourhimalayas/txt)
---

## 意大利一項3,451患者的研究表明羥氯喹顯著降低感染中共病毒住院患者死亡率達30%
`2020-09-06 00:39 Isaiah4031` [轉載自GNews](https://gnews.org/zh-hant/336616/)

![](https://s3.amazonaws.com/gnews-media-offload/wp-content/uploads/2020/09/05232439/20200825_HCQ_Italian_CORIST_photo.png)
意大利的CORIST多中心臨床試驗合作項目於2020年8月25日在《歐洲內科學雜誌》上發表了他們的一項最新研究。他們對意大利的住院感染中共病毒患者的死亡率進行了回顧性分析。根據意大利3,451名住院患者群組數據，相比未接受羥氯喹治療的患者，接受羥氯喹治療的患者死亡風險降低了約30%。

[閱讀英文全文](https://www.apple.com)

**Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study**

**對感染中共病毒的住院患者使用羥氯喹與死亡率的降低呈相關性：意大利****CORIST****回顧性多中心觀察研究的發現**

The COVID-19 RISK and Treatments (CORIST) Collaboration members

**Abstract****摘要**

**Background****背景**

Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19

羥氯喹（HCQ）被提議作為COVID-19的潛在治療方法

**Objective****目的**

We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality.

我們建立了一個意大利多中心臨床試驗合作項目，以研究HCQ治療與COVID-19住院死亡率之間的關係。

**Methods****方法**

In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses.

在一項回顧性觀察研究中，分析了2020年2月19日至2020年5月23日，在意大利33個臨床中心住院的3451名未經選擇的SARS-CoV-2實驗室確診感染的患者。事件時間分析的主要終點是住院死亡，將接受HCQ治療的患者與未接受HCQ治療的患者進行比較。我們使用逆向機率的多變量考克斯比例風險模型，來統計以傾向評分匹配權重的治療，並加上對分組的分析。

**Results****結果**

Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% lower risk of death in patients receiving HCQ (HR=0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry.

在3451名COVID-19患者中，76.3%接受了HCQ治療。接受與未接受HCQ的患者的死亡率（每千人/天）分別是8.9和15.7。調整傾向評分匹配後，我們發現接受HCQ的患者死亡風險降低30%（HR=0.70；95%CI：0.59至0.84；E值=1.67）。二次分析得出了類似的結果。HCQ與住院死亡率的反向關係在入院時C反應蛋白升高的患者中尤為明顯。

**Conclusions****結論**

HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.

在COVID-19住院患者中，使用HCQ與死亡風險降低30%是關聯的。在觀察性研究和還在等待中的隨機對照試驗結果的範圍內，這些數據並不妨礙在COVID-19住院患者中使用HCQ。

翻譯【Dlrow】編輯【Michelle】

戰友之家玫瑰園小隊出品

0
